Table of Contents

2019-2024 Global Primary Biliary Cholangitis Treatment Market Report (Status and Outlook)

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Primary Biliary Cholangitis Treatment Market Size 2014-2024
2.1.2 Primary Biliary Cholangitis Treatment Market Size CAGR by Region
2.2 Primary Biliary Cholangitis Treatment Segment by Type
2.2.1 Ursodeoxycholic Acid (UDCA)
2.2.2 Obeticholic Acid (Ocaliva)
2.3 Primary Biliary Cholangitis Treatment Market Size by Type
2.3.1 Global Primary Biliary Cholangitis Treatment Market Size Market Share by Type (2014-2019)
2.3.2 Global Primary Biliary Cholangitis Treatment Market Size Growth Rate by Type (2014-2019)
2.4 Primary Biliary Cholangitis Treatment Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Others
2.5 Primary Biliary Cholangitis Treatment Market Size by Application
2.5.1 Global Primary Biliary Cholangitis Treatment Market Size Market Share by Application (2014-2019)
2.5.2 Global Primary Biliary Cholangitis Treatment Market Size Growth Rate by Application (2014-2019)

3 Global Primary Biliary Cholangitis Treatment by Players
3.1 Global Primary Biliary Cholangitis Treatment Market Size Market Share by Players
3.1.1 Global Primary Biliary Cholangitis Treatment Market Size by Players (2017-2019)
3.1.2 Global Primary Biliary Cholangitis Treatment Market Size Market Share by Players (2017-2019)
3.2 Global Primary Biliary Cholangitis Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 Primary Biliary Cholangitis Treatment by Regions
4.1 Primary Biliary Cholangitis Treatment Market Size by Regions
4.2 Americas Primary Biliary Cholangitis Treatment Market Size Growth
4.3 APAC Primary Biliary Cholangitis Treatment Market Size Growth
4.4 Europe Primary Biliary Cholangitis Treatment Market Size Growth
4.5 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size Growth

5 Americas
5.1 Americas Primary Biliary Cholangitis Treatment Market Size by Countries
5.2 Americas Primary Biliary Cholangitis Treatment Market Size by Type
5.3 Americas Primary Biliary Cholangitis Treatment Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Primary Biliary Cholangitis Treatment Market Size by Countries
6.2 APAC Primary Biliary Cholangitis Treatment Market Size by Type
6.3 APAC Primary Biliary Cholangitis Treatment Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe
7.1 Europe Primary Biliary Cholangitis Treatment by Countries
7.2 Europe Primary Biliary Cholangitis Treatment Market Size by Type
7.3 Europe Primary Biliary Cholangitis Treatment Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Primary Biliary Cholangitis Treatment by Countries
8.2 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Type
8.3 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Global Primary Biliary Cholangitis Treatment Market Forecast
10.1 Global Primary Biliary Cholangitis Treatment Market Size Forecast (2019-2024)
10.2 Global Primary Biliary Cholangitis Treatment Forecast by Regions
10.2.1 Global Primary Biliary Cholangitis Treatment Forecast by Regions (2019-2024)
10.2.2 Americas Market Forecast
10.2.3 APAC Market Forecast
10.2.4 Europe Market Forecast
10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
10.3.1 United States Market Forecast
10.3.2 Canada Market Forecast
10.3.3 Mexico Market Forecast
10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
10.4.1 China Market Forecast
10.4.2 Japan Market Forecast
10.4.3 Korea Market Forecast
10.4.4 Southeast Asia Market Forecast
10.4.5 India Market Forecast
10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
10.5.1 Germany Market Forecast
10.5.2 France Market Forecast
10.5.3 UK Market Forecast
10.5.4 Italy Market Forecast
10.5.5 Russia Market Forecast
10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
10.6.1 Egypt Market Forecast
10.6.2 South Africa Market Forecast
10.6.3 Israel Market Forecast
10.6.4 Turkey Market Forecast
10.6.5 GCC Countries Market Forecast
10.7 Global Primary Biliary Cholangitis Treatment Forecast by Type
10.8 Global Primary Biliary Cholangitis Treatment Forecast by Application

11 Key Players Analysis
11.1 Novartis
11.1.1 Company Details
11.1.2 Primary Biliary Cholangitis Treatment Product Offered
11.1.3 Novartis Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.1.4 Main Business Overview
11.1.5 Novartis News
11.2 Bristol-Myers Squibb
11.2.1 Company Details
11.2.2 Primary Biliary Cholangitis Treatment Product Offered
11.2.3 Bristol-Myers Squibb Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.2.4 Main Business Overview
11.2.5 Bristol-Myers Squibb News
11.3 Pfizer
11.3.1 Company Details
11.3.2 Primary Biliary Cholangitis Treatment Product Offered
11.3.3 Pfizer Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.3.4 Main Business Overview
11.3.5 Pfizer News
11.4 GlaxoSmithKline
11.4.1 Company Details
11.4.2 Primary Biliary Cholangitis Treatment Product Offered
11.4.3 GlaxoSmithKline Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.4.4 Main Business Overview
11.4.5 GlaxoSmithKline News
11.5 Teva Pharmaceutical
11.5.1 Company Details
11.5.2 Primary Biliary Cholangitis Treatment Product Offered
11.5.3 Teva Pharmaceutical Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.5.4 Main Business Overview
11.5.5 Teva Pharmaceutical News
11.6 Retrophin
11.6.1 Company Details
11.6.2 Primary Biliary Cholangitis Treatment Product Offered
11.6.3 Retrophin Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.6.4 Main Business Overview
11.6.5 Retrophin News
11.7 Lumena Pharmaceuticals
11.7.1 Company Details
11.7.2 Primary Biliary Cholangitis Treatment Product Offered
11.7.3 Lumena Pharmaceuticals Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.7.4 Main Business Overview
11.7.5 Lumena Pharmaceuticals News
11.8 Intercept Pharmaceuticals
11.8.1 Company Details
11.8.2 Primary Biliary Cholangitis Treatment Product Offered
11.8.3 Intercept Pharmaceuticals Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
11.8.4 Main Business Overview
11.8.5 Intercept Pharmaceuticals News

12 Research Findings and Conclusion